267 related articles for article (PubMed ID: 30467380)
1. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers.
Gooding AJ; Zhang B; Gunawardane L; Beard A; Valadkhan S; Schiemann WP
Oncogene; 2019 Mar; 38(12):2020-2041. PubMed ID: 30467380
[TBL] [Abstract][Full Text] [Related]
2. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
3. LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer.
Xu Y; Ren W; Li Q; Duan C; Lin X; Bi Z; You K; Hu Q; Xie N; Yu Y; Xu X; Hu H; Yao H
Cancer Res; 2022 Feb; 82(4):556-570. PubMed ID: 34965935
[TBL] [Abstract][Full Text] [Related]
4. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
5. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
6. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
7. Long Non-Coding RNA (lncRNA) BMP/OP-Responsive Gene (BORG) Promotes Development of Chemoresistance of Colorectal Cancer Cells to Carboplatin.
Li J; Ma J; Zhang X; Tai X; Liu L; Zhang L
Med Sci Monit; 2020 Jan; 26():e919103. PubMed ID: 31937750
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
[TBL] [Abstract][Full Text] [Related]
9. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
House CD; Grajales V; Ozaki M; Jordan E; Wubneh H; Kimble DC; James JM; Kim MK; Annunziata CM
BMC Cancer; 2018 May; 18(1):595. PubMed ID: 29801480
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
[TBL] [Abstract][Full Text] [Related]
11. The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence.
Gooding AJ; Zhang B; Jahanbani FK; Gilmore HL; Chang JC; Valadkhan S; Schiemann WP
Sci Rep; 2017 Oct; 7(1):12698. PubMed ID: 28983112
[TBL] [Abstract][Full Text] [Related]
12. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
13. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
14. lncRNA BORG:TRIM28 Complexes Drive Metastatic Progression by Inducing α6 Integrin/CD49f Expression in Breast Cancer Stem Cells.
Parker KA; Gooding AJ; Valadkhan S; Schiemann WP
Mol Cancer Res; 2021 Dec; 19(12):2068-2080. PubMed ID: 34497119
[TBL] [Abstract][Full Text] [Related]
15. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
17. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
18. The IncRNA BORG: A novel inducer of TNBC metastasis, chemoresistance, and disease recurrence.
Gooding AJ; Parker KA; Valadkhan S; Schiemann WP
J Cancer Metastasis Treat; 2019; 5():. PubMed ID: 31435529
[TBL] [Abstract][Full Text] [Related]
19. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
Zheng S; Li M; Miao K; Xu H
J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
[TBL] [Abstract][Full Text] [Related]
20. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
Sirois I; Aguilar-Mahecha A; Lafleur J; Fowler E; Vu V; Scriver M; Buchanan M; Chabot C; Ramanathan A; Balachandran B; Légaré S; Przybytkowski E; Lan C; Krzemien U; Cavallone L; Aleynikova O; Ferrario C; Guilbert MC; Benlimame N; Saad A; Alaoui-Jamali M; Saragovi HU; Josephy S; O'Flanagan C; Hursting SD; Richard VR; Zahedi RP; Borchers CH; Bareke E; Nabavi S; Tonellato P; Roy JA; Robidoux A; Marcus EA; Mihalcioiu C; Majewski J; Basik M
Mol Cancer Res; 2019 Dec; 17(12):2492-2507. PubMed ID: 31537618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]